Terwisscha van Scheltinga A - Search Results

1

ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.

Kol A, Terwisscha van Scheltinga A, Pool M, Gerdes C, de Vries E, de Jong S. Kol A, et al. Among authors: terwisscha van scheltinga a. Oncotarget. 2017 Jul 11;8(28):45432-45446. doi: 10.18632/oncotarget.17139. Oncotarget. 2017. PMID: 28467975 Free PMC article.

2

Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.

Pool M, Kol A, Lub-de Hooge MN, Gerdes CA, de Jong S, de Vries EG, Terwisscha van Scheltinga AG. Pool M, et al. Among authors: terwisscha van scheltinga ag. Oncotarget. 2016 Oct 18;7(42):68111-68121. doi: 10.18632/oncotarget.11827. Oncotarget. 2016. PMID: 27602494 Free PMC article.

3

HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.

Kol A, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EG, Schröder CP. Kol A, et al. Among authors: terwisscha van scheltinga ag. Pharmacol Ther. 2014 Jul;143(1):1-11. doi: 10.1016/j.pharmthera.2014.01.005. Epub 2014 Feb 7. Pharmacol Ther. 2014. PMID: 24513440 Review.

4

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

ter Weele EJ, Terwisscha van Scheltinga AG, Kosterink JG, Pot L, Vedelaar SR, Lamberts LE, Williams SP, Lub-de Hooge MN, de Vries EG. ter Weele EJ, et al. Oncotarget. 2015 Dec 8;6(39):42081-90. doi: 10.18632/oncotarget.5877. Oncotarget. 2015. PMID: 26536664 Free PMC article.

5

⁸⁹Zr-Onartuzumab PET imaging of c-MET receptor dynamics.

Pool M, Terwisscha van Scheltinga AGT, Kol A, Giesen D, de Vries EGE, Lub-de Hooge MN. Pool M, et al. Among authors: terwisscha van scheltinga agt. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1328-1336. doi: 10.1007/s00259-017-3672-x. Epub 2017 Mar 19. Eur J Nucl Med Mol Imaging. 2017. PMID: 28315949 Free PMC article.

6

⁸⁹Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

Pool M, Kol A, de Jong S, de Vries EGE, Lub-de Hooge MN, Terwisscha van Scheltinga AGT. Pool M, et al. Among authors: terwisscha van scheltinga agt. MAbs. 2017 Nov/Dec;9(8):1370-1378. doi: 10.1080/19420862.2017.1371382. Epub 2017 Sep 5. MAbs. 2017. PMID: 28873009 Free PMC article.

7

MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.

Stutvoet TS, Kol A, de Vries EG, de Bruyn M, Fehrmann RS, Terwisscha van Scheltinga AG, de Jong S. Stutvoet TS, et al. Among authors: terwisscha van scheltinga ag. J Pathol. 2019 Sep;249(1):52-64. doi: 10.1002/path.5280. Epub 2019 May 21. J Pathol. 2019. PMID: 30972766 Free PMC article.

8

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.

van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK. van der Bilt AR, et al. Clin Cancer Res. 2012 Nov 15;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. Epub 2012 Sep 26. Clin Cancer Res. 2012. PMID: 23014526

9

⁸⁹Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, de Vries EGE. Bensch F, et al. Among authors: terwisscha van scheltinga agt. Clin Cancer Res. 2017 Oct 15;23(20):6128-6137. doi: 10.1158/1078-0432.CCR-17-0311. Epub 2017 Jul 21. Clin Cancer Res. 2017. PMID: 28733442 Free PMC article. Clinical Trial.

10

Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.

Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schröder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG. Terwisscha van Scheltinga AG, et al. J Nucl Med. 2011 Nov;52(11):1778-85. doi: 10.2967/jnumed.111.092833. Epub 2011 Oct 11. J Nucl Med. 2011. PMID: 21990576 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page